FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170655985> ?p ?o ?g. }

• W2170655985 endingPage "2555" @default.
• W2170655985 startingPage "2544" @default.
• W2170655985 abstract "Purpose Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl (Tarceva, OSI-774; OSI Pharmaceuticals, New York, NY) is a potent, reversible, highly selective and orally available HER-1/epidermal growth factor receptor tyrosine kinase inhibitor. Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non–small-cell lung cancer (NSCLC). Patients and Methods A phase I/II study in two centers examined erlotinib and bevacizumab (A+T) in patients with nonsquamous stage IIIB/IV NSCLC with ≥ one prior chemotherapy. In phase I, erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days was established as the phase II dose, although no dose-limiting toxicities were observed. Phase II assessed the efficacy and tolerability of A+T at this dose. Pharmacokinetic parameters were evaluated. Results Forty patients were enrolled and treated in this study (34 patients at phase II dose); the median age was 59 years (range, 36 to 72 years), 21 were female, 30 had adenocarcinoma histology, nine were never-smokers, and 22 had ≥ two prior regimens (three patients had ≥ four prior regimens). The most common adverse events were mild to moderate rash, diarrhea, and proteinuria. Preliminary data showed no pharmacokinetic interaction between A+T. Eight patients (20.0%; 95% CI, 7.6% to 32.4%) had partial responses and 26 (65.0%; 95% CI, 50.2% to 79.8%) had stable disease as their best response. The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months. Conclusion Encouraging antitumor activity and safety of A+T support further development of this combination for patients with advanced NSCLC and other solid tumors." @default.
• W2170655985 created "2016-06-24" @default.
• W2170655985 creator A5008593691 @default.
• W2170655985 creator A5008842387 @default.
• W2170655985 creator A5017346729 @default.
• W2170655985 creator A5018054686 @default.
• W2170655985 creator A5026453430 @default.
• W2170655985 creator A5031968057 @default.
• W2170655985 creator A5032491249 @default.
• W2170655985 creator A5041570474 @default.
• W2170655985 creator A5052461112 @default.
• W2170655985 creator A5056211639 @default.
• W2170655985 creator A5056267838 @default.
• W2170655985 creator A5057109001 @default.
• W2170655985 creator A5057281549 @default.
• W2170655985 creator A5059652753 @default.
• W2170655985 creator A5067386747 @default.
• W2170655985 creator A5068495779 @default.
• W2170655985 creator A5078389632 @default.
• W2170655985 creator A5080439835 @default.
• W2170655985 creator A5085188591 @default.
• W2170655985 creator A5088898639 @default.
• W2170655985 date "2005-04-10" @default.
• W2170655985 modified "2023-10-11" @default.
• W2170655985 title "Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer" @default.
• W2170655985 cites W1220249624 @default.
• W2170655985 cites W1664817186 @default.
• W2170655985 cites W1969257771 @default.
• W2170655985 cites W1972534538 @default.
• W2170655985 cites W1974165456 @default.
• W2170655985 cites W1976806852 @default.
• W2170655985 cites W1982005589 @default.
• W2170655985 cites W1985712533 @default.
• W2170655985 cites W1986727868 @default.
• W2170655985 cites W2002602526 @default.
• W2170655985 cites W2015157808 @default.
• W2170655985 cites W2043696829 @default.
• W2170655985 cites W2046507292 @default.
• W2170655985 cites W2047083378 @default.
• W2170655985 cites W2049484790 @default.
• W2170655985 cites W2064273319 @default.
• W2170655985 cites W2068014745 @default.
• W2170655985 cites W2080267208 @default.
• W2170655985 cites W2100785570 @default.
• W2170655985 cites W2101055110 @default.
• W2170655985 cites W2103134643 @default.
• W2170655985 cites W2113257521 @default.
• W2170655985 cites W2124054226 @default.
• W2170655985 cites W2135836172 @default.
• W2170655985 cites W2138604360 @default.
• W2170655985 cites W2139248078 @default.
• W2170655985 cites W2145224595 @default.
• W2170655985 cites W2145854263 @default.
• W2170655985 cites W2161821474 @default.
• W2170655985 cites W2258529761 @default.
• W2170655985 cites W2278057905 @default.
• W2170655985 cites W2280647462 @default.
• W2170655985 cites W43664894 @default.
• W2170655985 doi "https://doi.org/10.1200/jco.2005.02.477" @default.
• W2170655985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15753462" @default.
• W2170655985 hasPublicationYear "2005" @default.
• W2170655985 type Work @default.
• W2170655985 sameAs 2170655985 @default.
• W2170655985 citedByCount "498" @default.
• W2170655985 countsByYear W21706559852012 @default.
• W2170655985 countsByYear W21706559852013 @default.
• W2170655985 countsByYear W21706559852014 @default.
• W2170655985 countsByYear W21706559852015 @default.
• W2170655985 countsByYear W21706559852016 @default.
• W2170655985 countsByYear W21706559852017 @default.
• W2170655985 countsByYear W21706559852018 @default.
• W2170655985 countsByYear W21706559852019 @default.
• W2170655985 countsByYear W21706559852020 @default.
• W2170655985 countsByYear W21706559852021 @default.
• W2170655985 countsByYear W21706559852022 @default.
• W2170655985 countsByYear W21706559852023 @default.
• W2170655985 crossrefType "journal-article" @default.
• W2170655985 hasAuthorship W2170655985A5008593691 @default.
• W2170655985 hasAuthorship W2170655985A5008842387 @default.
• W2170655985 hasAuthorship W2170655985A5017346729 @default.
• W2170655985 hasAuthorship W2170655985A5018054686 @default.
• W2170655985 hasAuthorship W2170655985A5026453430 @default.
• W2170655985 hasAuthorship W2170655985A5031968057 @default.
• W2170655985 hasAuthorship W2170655985A5032491249 @default.
• W2170655985 hasAuthorship W2170655985A5041570474 @default.
• W2170655985 hasAuthorship W2170655985A5052461112 @default.
• W2170655985 hasAuthorship W2170655985A5056211639 @default.
• W2170655985 hasAuthorship W2170655985A5056267838 @default.
• W2170655985 hasAuthorship W2170655985A5057109001 @default.
• W2170655985 hasAuthorship W2170655985A5057281549 @default.
• W2170655985 hasAuthorship W2170655985A5059652753 @default.
• W2170655985 hasAuthorship W2170655985A5067386747 @default.
• W2170655985 hasAuthorship W2170655985A5068495779 @default.
• W2170655985 hasAuthorship W2170655985A5078389632 @default.
• W2170655985 hasAuthorship W2170655985A5080439835 @default.
• W2170655985 hasAuthorship W2170655985A5085188591 @default.
• W2170655985 hasAuthorship W2170655985A5088898639 @default.
• W2170655985 hasBestOaLocation W21706559851 @default.

• next